2-氨基-4-甲基-5-苯基恶唑啉 | 3568-94-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-4-甲基-5-苯基恶唑啉
• 中文别名: 甲米雷司
• 英文名称: 4-methylaminorex
• 英文别名: 2-Amino-4-methyl-5-phenyl-oxazolin；2-Amino-4-methyl-5-phenyloxazolin；4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine
• CAS: 3568-94-3
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: LJQBMYDFWFGESC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  甲基苯乙烯 、 尿素 在 Selectfluor 、 lithium iodide 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以35%的产率得到5-methyl-4-phenyl-4,5-dihydrooxazol-2-amine
  参考文献：
  名称：

  尿素底物的区域选择性形式[3 + 2]环加成反应，用于分子间烯烃氨加氧反应的活化和未活化烯烃

  摘要：

  描述了一类新的分子间烯烃氨氧化反应。该反应利用经典的intermediate中间体作为区域和立体化学模板来完成活化和未活化烯烃的选择性氧化胺化反应。值得注意的是，可以将尿素化学原料直接作为N和O源引入，并且可以将简单的碘化物盐用作催化剂。正式的[3 + 2]环加成过程为具有有用的选择性和官能团耐受性的一系列有用杂环产品提供了高度模块化的入口。

  DOI：

  10.1002/anie.201904662

文献信息

• DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE
  申请人：Johansen Jon Eigill

  公开号：US20140227792A1

  公开（公告）日：2014-08-14

  Deuterium free, stable isotope labeled hallucinogens and/or stimulants containing a 2-phenylethylamine-based structural unit and containing at least three stable isotopes selected from the group consisting of 13 C, 15 N and 18 O as free bases and as their salts; method of their preparation and their use in the chemical analysis, in particular forensic chemical analysis, and in metabolic studies.

  不含氘的、稳定同位素标记的致幻剂和/或兴奋剂，含有基于2-苯乙胺的结构单元，并且至少含有来自13C、15N和18O组成的稳定同位素中的三种作为自由碱和其盐的方法；它们的制备方法及其在化学分析中的使用，特别是在法医化学分析和代谢研究中的应用。
• TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS
  申请人：CHIRON AS

  公开号：US20150204893A1

  公开（公告）日：2015-07-23

  A test kit for the quantitative determination of narcotic drugs comprising (A) series of sealed vessels, each vessel containing a deuterium free isotopologue of a narcotic drug in exactly defined concentrations and quantities, wherein the isotopologue differs from vessel to vessel and—wherein the quantities of the isotopologue differ from vessel to vessel or are the same for all vessels; and/or (B) series of sealed vessels, each vessel containing in exactly defined concentrations and quantities the same isotopologue in quantities which differ from vessel to vessel; wherein the free isotopologues are selected from narcotic drugs; prodrugs, salts, solvates, hydrates and polymorphs and contain at least three stable isotopes selected from the group consisting of 13 C, 15 N and 18 O in the molecule with a degree of labeling of at least 95 mol-%; the use of the test kit and a method for quantitatively determining narcotic drugs.

  一种用于定量测定麻醉药物的检测试剂盒，包括（A）一系列密封容器，每个容器中含有一种去氘同位素麻醉药物，其浓度和数量均被精确定义，其中同位素从容器到容器不同，同位素的数量在容器到容器之间不同或对所有容器都相同；和/或（B）一系列密封容器，每个容器中含有相同的同位素，其浓度和数量被精确定义，数量在容器到容器之间不同；其中自由同位素选自麻醉药物、前药、盐、溶剂、水合物和多晶形，并且在分子中至少包含三种稳定同位素，所述稳定同位素选自13C、15N和18O，其标记度至少为95摩尔％；使用该检测试剂盒和一种定量测定麻醉药物的方法。
• Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use
  申请人：Chiron AS

  公开号：EP2551675A1

  公开（公告）日：2013-01-30

  Deuterium free, stable isotope labeled hallucinogens and/or stimulants containing a 2-phenylethylamine-based structural unit and containing at least three stable isotopes selected from the group consisting of 13C, 15N and 18O as free bases and as their salts; method of their preparation and their use in the chemical analysis, in particular forensic chemical analysis, and in metabolic studies.

  不含氘的稳定同位素标记致幻剂和/或兴奋剂，含有一个以 2-苯基乙胺为基础的结构单元，并含有至少三个从 13C、15N 和 18O 组成的组中选出的稳定同位素作为游离碱及其盐；其制备方法及其在化学分析（特别是法医化学分析）和新陈代谢研究中的用途。
• Test kit for the quantitative determination of narcotic drugs
  申请人：Chiron AS

  公开号：EP2687854A1

  公开（公告）日：2014-01-22

  A test kit for the quantitative determination of narcotic drugs comprising (A) series of sealed vessels, each vessel containing a deuterium free isotopologue of a narcotic drug in exactly defined concentrations and quantities, - wherein the isotopologue differs from vessel to vessel and - wherein the quantities of the isotopologue differ from vessel to vessel or are the same for all vessels; and/or (B) series of sealed vessels, each vessel containing in exactly defined concentrations and quantities the same isotopologue in quantities which differ from vessel to vessel; - wherein the free isotopologues are selected from narcotic drugs; prodrugs, salts, solvates, hydrates and polymorphs and contain at least three stable isotopes selected from the group consisting of 13C, 15N and 18O in the molecule with a degree of labeling of at least 95 mol-%; the use of the test kit and a method for quantitatively determining narcotic drugs.

  用于定量测定麻醉药品的试剂盒，包括 (A) 一系列密封容器，每个容器装有浓度和数量完全确定的麻醉药品的无 氘同位素、 - 其中各容器的同位素不同，并且 - 其中同位素的数量因容器而异或所有容器相同；和/或 (B) 一系列密封容器，每个容器以完全确定的浓度和数量含有相同的同位 素，其数量因容器而异； - 其中游离的同位素选自麻醉药品；原药、盐、溶液、水合物和多晶型物，以及 分子中至少含有三个稳定同位素，选自 13C、15N 和 18O 组成的组，标记度至少为 95 摩尔-%； 使用检测试剂盒和方法定量测定麻醉药品。
• COMBINATION TREATMENT COMPRISING BUPROPION ( (±)-2-(TERT-BUTYLAMINO)-1-(3-CHLOROPHENYL)PROPAN-1-ONE) AND A SYMPATHOMIMETIC DRUG FOR WEIGHT CONTROL AND TREATING OBESITY
  申请人：Winston Thomas R.

  公开号：US20160022610A1

  公开（公告）日：2016-01-28

  Compositions and methods for controlling weight gain and treating obesity are disclosed. Compositions include bupropion and a sympathomimetic drug. Methods for controlling weight include administering a composition including a combination of bupropion and a sympathomimetic drug. Methods for treating obesity include administering a composition including a combination of bupropion and a sympathomimetic drug. The active agents of the composition may be administered at a lower dosages than either drug separately with less side effect risk and allow for longer periods of administration to increase the time for controlling weight loss and treating obesity.